Gilgamesh Pharmaceuticals is focused on developing innovative new chemical entities (NCEs) aimed at addressing the underlying causes of neurological diseases, particularly in the realm of mental health. Their approach emphasizes the creation of rapid-acting and long-lasting therapies, moving beyond traditional symptom management. The company leverages deep expertise in medicinal chemistry alongside an AI-powered discovery and translational platform to accelerate the development of precision psychiatric therapies. Their pipeline includes a range of promising candidates, such as orally bioavailable NMDAR antagonists and 5-HT2A agonists, which are designed to provide rapid relief from conditions like depression and anxiety while minimizing adverse effects.

The technologies being developed by Gilgamesh Pharmaceuticals include non-hallucinogenic neuroplastogens and safer ibogaine analogs, which are engineered to enhance safety and efficacy for various indications, including opioid use disorder and PTSD. These NCEs are characterized by their rapid action, improved cardiac safety profiles, and optimized duration of effect, making them suitable for potential at-home use. The company is currently advancing several programs through different stages of clinical development, with a strong emphasis on improving dosing convenience and overall patient outcomes in the treatment of mental health disorders.

United States

Gilgamesh is a clinical-stage biotech whose vision is to reshape how mental illnesses are treated by shifting away from symptom management to a focus on rapid-acting and durable therapies targeting the fundamental drivers of disease. We do this by designing best-in-class new chemical entities (NCEs) acting through proven mechanisms, which are optimized for safety, efficacy, and patient access

Gilgamesh Pharmaceuticals

Company Details